Interferon tau

Summary

Interferon tau (IFN-τ) is a type I interferon originally identified in ruminants (sheep, cattle) as the signal of maternal recognition of pregnancy. It is produced by the trophoblast and prevents luteolysis. It has demonstrated potent antiviral and immunomodulatory properties in preclinical models and early human studies, with potential therapeutic applications in autoimmune diseases (e.g., multiple sclerosis, inflammatory bowel disease) and viral infections. Its lower toxicity profile compared to IFN-alpha at equivalent doses makes it an attractive research candidate.

Mechanism of Action

Binds to the type I interferon receptor (IFNAR1/IFNAR2) and activates the JAK-STAT signaling pathway (JAK1/TYK2), inducing expression of interferon-stimulated genes (ISGs) with antiviral, antiproliferative, and immunomodulatory effects; notably signals via STAT1 and STAT2 without activating STAT4, and does not suppress luteal function at low doses, distinguishing it from IFN-alpha

Routes of Administration

Goals & Uses

• Multiple sclerosis treatmentAutoimmune / NeuroinflammatoryLow
• Lupus / SLEAutoimmuneUnknown
• Antiviral activityInfectious DiseaseLow
• Immunomodulation in autoimmune diseasesAutoimmuneLow
• Inflammatory bowel diseaseGastroenterologyLow

Contraindications

• Severe hepatic impairmentOrganModerateLiver function concerns
• Severe psychiatric disordersPsychiatricModerate
• Autoimmune hepatitisHepatic / AutoimmuneHigh
• Hypersensitivity to interferon tau or excipientsAllergy / ImmunologicHigh

Adverse Effects

• HepatotoxicityHepaticUncommonLiver injury or dysfunction
• Injection site reactionsLocalCommon
• Flu-like symptoms (fever, chills, myalgia)SystemicCommon
• Neuropsychiatric effectsNeurological / PsychiatricUncommon
• Hematologic changes (leukopenia, thrombocytopenia)HematologicUncommon
• FatigueGeneralCommonLow energy or tiredness

Drug Interactions

• Myelosuppressive agentsModerate
• Immunosuppressants (e.g., corticosteroids)Moderate
• Hepatotoxic drugsModerate

Population Constraints

• PregnancyReproductive SafetyRelative
• Renal impairmentOrgan ImpairmentRelative
• Pediatric populationsAgeRelative
• Pre-existing autoimmune conditionsAutoimmuneRelative

Regulatory Status

• European UnionInvestigationalNo EMA marketing authorization; research and investigational use only
• United StatesInvestigationalStudied under IND for multiple sclerosis and other conditions; not FDA approved for any indication
• United KingdomInvestigationalNo MHRA approval; research use only

Not approved by FDA, EMA, or other major regulatory agencies for any therapeutic indication. Studied in Phase I/II clinical trials for multiple sclerosis and other autoimmune conditions. Used primarily in research and preclinical settings.

Evidence & Sources

No sources recorded yet.